The short answer
Calcium may be part of your osteoporosis care, but it should not be swallowed with risedronate. Calcium can reduce absorption of the medicine. Standard tablets and delayed-release Atelvia have different breakfast instructions; both labels place calcium supplements at a different time of day.
What this answer covers
Oral calcium supplements with immediate-release or delayed-release oral risedronate sodium. Adequate total calcium intake and separation of a supplement dose are separate decisions.
- Supplement or preparation
- Calcium
- Medication ingredient
- risedronate
Why does this combination need attention?
The current labels identify calcium as an absorption-interfering product. Atelvia labeling reports a crossover study in 101 postmenopausal women: adding a tablet with 600 mg elemental calcium and 400 IU vitamin D after breakfast reduced risedronate exposure by about 38%. This is not a measured effect of every calcium salt or vitamin D alone.
How should the doses be scheduled?
For standard immediate-release risedronate, take the medicine before breakfast with plain water and observe the initial 30-minute wait before food or oral products. The labels additionally place calcium, antacids, magnesium and iron at another time of day. Atelvia is instead taken immediately after breakfast. Confirm the formulation before applying either routine; delayed release does not remove the mineral separation instructions.
What should I discuss with my pharmacist?
Review dietary calcium and all supplement labels with your clinician. Supplemental calcium is recommended when dietary intake is inadequate; not every person needs the same extra dose. Low blood calcium and other mineral disturbances should be addressed before treatment. Discuss a later meal as a practical place for the supplement.
What are the limits of the evidence?
The major risedronate trial supplied calcium and vitamin D at a different meal. Its favorable bone-density results support that separated regimen, not taking calcium with the medicine. No study here establishes a safe simultaneous calcium dose or shows that one calcium form bypasses the interaction. Do not increase risedronate after a scheduling error.
Evidence and practical considerations
Absorption & effectiveness
Calcium may be part of your osteoporosis care, but it should not be swallowed with risedronate. Calcium can reduce absorption of the medicine. Standard tablets and delayed-release Atelvia have different breakfast instructions; both labels place calcium supplements at a different time of day.
- Exact scope
- Oral calcium supplements with immediate-release or delayed-release oral risedronate sodium. Adequate total calcium intake and separation of a supplement dose are separate decisions. with oral immediate-release risedronate sodium; oral delayed-release risedronate sodium
- Medication form and route
- oral immediate-release risedronate sodium; oral delayed-release risedronate sodium
- Timing or duration
- Timing applies on each prescribed oral dose day. Nutrient adequacy is an ongoing treatment consideration. Clinical trial durations and limitations are recorded in each source.
What remains uncertain
- The major risedronate trial supplied calcium and vitamin D at a different meal. Its favorable bone-density results support that separated regimen, not taking calcium with the medicine. No study here establishes a safe simultaneous calcium dose or shows that one calcium form bypasses the interaction. Do not increase risedronate after a scheduling error.
Factors that may matter: Medication route and release formulation; Supplement mineral content and chemical preparation; Timing relative to breakfast and other oral products; Dietary intake and pre-existing mineral or vitamin deficiency.
Read the supporting source summaries
Source 1: current U.S. regulatory prescribing information
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: Patients taking immediate-release oral risedronate sodium tablets for approved bone indications.
The medicine is taken before breakfast and other oral products with an initial 30-minute interval. Calcium, antacids, magnesium products and iron are scheduled at a different time of day. Calcium and vitamin D adequacy is recommended, with supplementation if dietary intake is inadequate.
How this applies: Applies to oral calcium-containing medicinal or supplement products under the stated medication formulation. Individual salt effects and quantitative outcome differences are not established. Exact scope: Oral calcium supplements with immediate-release or delayed-release oral risedronate sodium. Adequate total calcium intake and separation of a supplement dose are separate decisions.
Product instructions and class-based absorption precautions do not quantify every individual mineral salt. They must not be substituted for delayed-release dosing instructions.
Source 2: current U.S. regulatory prescribing information
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: Postmenopausal women receiving delayed-release oral risedronate 35 mg; absorption crossover included 101 postmenopausal women.
Co-administration of the combination supplement reduced risedronate exposure approximately 38%. The label places calcium, antacids, magnesium products and iron at a different time of day and specifies Atelvia immediately after breakfast.
How this applies: Applies to oral calcium-containing medicinal or supplement products under the stated medication formulation. Individual salt effects and quantitative outcome differences are not established. Exact scope: Oral calcium supplements with immediate-release or delayed-release oral risedronate sodium. Adequate total calcium intake and separation of a supplement dose are separate decisions.
The absorption study used a combined calcium-vitamin D product and cannot isolate vitamin D, another mineral or every calcium salt. The 38% estimate is not transferable to all formulations or supplements.
Source 3: peer-reviewed randomized clinical trial
europepmc.org · Source check Sep 10, 2026
Population: 922 treated postmenopausal women with osteoporosis; immediate-release daily group n=307, delayed-release before-breakfast n=308 and after-breakfast n=307.
Delayed-release regimens were non-inferior on lumbar-spine bone mineral density. The supplement instructions deliberately separated calcium and vitamin D from risedronate.
How this applies: Direct evidence for risedronate formulation schedules, with separated calcium/vitamin D use. It does not test simultaneous calcium co-administration. Exact scope: Oral calcium supplements with immediate-release or delayed-release oral risedronate sodium. Adequate total calcium intake and separation of a supplement dose are separate decisions.
Formulation efficacy study, not a simultaneous mineral co-administration trial. All subjects received supplements; their necessity, independent effects and optimal individual doses were not randomized. The older before-breakfast trial arm does not override current Atelvia after-breakfast instructions.
Research assessment: · Open full citations ↗
Review and change history
- Publication status
- Published research summary
- Clinical review
- Not yet recorded
| Date | Update |
|---|---|
| Article prepared | |
| Current oral formulation labels, route boundaries and original dosing evidence assessed. Exact existing statements adjudicated and article prepared. Clinical sign-off not recorded. | |
| Research summary published |
Article revision: d34e9ff7feb6dedd
This guide brings together the evidence records used by our interaction checker. Each finding retains its own preparation limits, research date, and source summaries.
Full citations require verification. Reading this answer and the source summaries does not.
Taking other supplements or medications?
Use the checker to explore your other combinations. Ask a pharmacist to review the exact products, amounts and medical conditions in your complete list.
Open the interaction checkerInformation, not medical advice. Do not change prescribed treatment based on this guide.